(12) **Translation of European patent specification**

(11) **NO/EP 2975042 B1**

NORWAY

(19) NO

(51) Int Cl.

C07D 495/04 (2006.01)
A61K 31/4365 (2006.01)
A61P 35/00 (2006.01)
C07D 409/12 (2006.01)

Norwegian Industrial Property Office

(21)	Translation Published	2019.02.25
(80)	Date of The European Patent Office Publication of the Granted Patent	2018.10.03
(86)	European Application Nr.	15181011.6
(86)	European Filing Date	2011.06.20
(87)	The European Application's Publication Date	2016.01.20
(30)	Priority	2010.06.23, KR, 20100059686
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
(62)	Divided application	EP2585470, 2011.06.20
(73)	Proprietor	Hanmi Science Co., Ltd., 550, Dongtangiheung-ro Dongtan-myeon, Hwaseong-si, Gyeonggi-do 445-813, Sør-Korea
(72)	Inventor	CHA, Mi Young, Hanlla Apt. 306-1102, Cheongsolmaeul,Geumgok-dong,Bundang-gu,Seongnam-si, 463-725 Gyeonggi-do, Sør-Korea KANG, Seok Jong, 174-1, Jamo-ri,Gunbuk-myeon,Okcheon-gun,, 373-853 Chungcheong-buk-do, Sør-Korea KIM, Mi Ra, 102-ho, 7-31, Yangjae-dong,Seocho-gu, 137-130 Seoul, Sør-Korea LEE, Ju Yeon, Hoban 2-cha Apt. 215-202,Wolgae-dong,Gwangsan-gu,, 506-773 Gwangju, Sør-Korea JEON, Ji Young, Mokryeon Apt. 1213-202,Sanbon-dong,Gunpo-si,, 435-040 Gyeonggi-do, Sør-Korea JO, Myoung Gi, Seongwon 2-cha 202-1106,Anyang-4-dong,Manan-gu,Anyang-si,, 430-014 Gyeonggi-do, Sør-Korea KWAK, Eun Joo, 303-4, Seogwi-dong,Seogwipo-si,, 679-010 Jeju-do, Sør-Korea LEE, Kwang Ok, LG Xi Apt. 912-401,Sanghyeon-2-dong,Suji-gu,Yongin-si,, 448-132 Gyeonggi-do, Sør-Korea HA, Tae Hee, Seohae Grable 413-2101,Solbitmaeul,Bansong-dong,Hwaseong-si,, 445-758 Gyeonggi-do, Sør-Korea SUH, Kwee Hyun, 225-502, 24, Dongsuwon-ro 145beon-gil,Gwonseon-gu,Suwon-si, Gyeonggi-do 16663, Sør-Korea KIM, Maeng Sup, Dunchon Jugong Apt. 301-203,Dunchon-dong,Gangdong-gu,, 134-060 Seoul, Sør-Korea

(74) Agent or Attorney TANDBERG INNOVATION AS, Postboks 1570 Vika, 0118 OSLO, Norge

(54) Title **NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY**

(56) References Cited: WO-A1-2009/158571, WO-A2-2010/054285, WO-A1-2009/062258

Patentkrav

1. Forbindelse med formel (I) eller et farmasøytisk akseptabelt salt derav:



(I)

hvori,

W er O eller S;

X er O, NH, S, SO eller SO_2;

Y er hydrogenatom, halogenatom, C_{1-6}alkyl eller C_{1-6}alkoksy;

A og B er hver uavhengig hydrogenatom, halogenatom, eller di(C_{1-6}alkyl)aminometyl;

Z er aryl eller heteroaryl som har en eller flere substituenter valgt fra gruppen som består av: hydrogenatom, halogenatom, hydroksy, nitro, cyano, C_{1-6}alkyl, C_{1-6}alkoksy, C_{1-6}alkylkarbonyl, C_{1-6}alkoksykarbonyl, di(C_{1-6}alkyl)aminoC_{2-6}alkoksykarbonyl, amino, C_{1-6}alkylamino, di(C_{1-6}alkyl)amino, karbamoyl, C_{1-6}alkylkarbamoyl, di(C_{1-6}alkyl)karbamoyl, di(C_{1-6}alkyl)aminoC_{2-6}alkylkarbamoyl, sulfamoyl, C_{1-6}alkylsulfamoyl, di(C_{1-6}alkyl)sulfamoyl, di(C_{1-6}alkyl)aminoC_{2-6}alkylsulfamoyl, C_{1-6}alkylsulfonyl, C_{1-6}alkylsulfinyl, di(C_{1-6}alkyl)fosfonyl, hydroksyC_{1-6}alkyl, hydroksykarbonylC_{1-6}alkyl, C_{1-6}alkoksyC_{1-6}alkyl, C_{1-6}alkylsulfonylC_{1-6}alkyl, C_{1-6}alkylsulfinylC_{1-6}alkyl, di(C_{1-6}alkyl)fosfonylC_{1-6}alkyl, hydroksyC_{2-6}alkoksy, C_{1-6}alkoksyC_{2-6}alkoksy, aminoC_{1-6}alkyl, C_{1-6}alkylaminoC_{1-6}alkyl, di(C_{1-6}alkyl)aminoC_{1-6}alkyl, di(C_{1-6}alkyl)aminoacetyl, aminoC_{2-6}alkoksy, C_{1-6}alkylaminoC_{2-6}alkoksy, di(C_{1-6}alkyl)aminoC_{2-6}alkoksy, hydroksyC_{2-6}alkylamino, C_{1-6}alkoksyC_{2-6}alkylamino, aminoC_{2-6}alkylamino, C_{1-6}alkylaminoC_{2-6}alkylamino, di(C_{1-6}alkyl)aminoC_{2-6}alkylamino, heteroaryl, heterosyklus, heterosyklisk oksy, heterosyklisk tio, heterosyklisk sulfinyl, heterosyklisk sulfonyl, heterosyklisk sulfamoyl, heterosyklisk C_{1-6}alkyl, heterosyklisk C_{1-6}alkoksy, heterosyklisk amino, heterosyklisk C_{1-6}alkylamino, heterosyklisk aminoC_{1-6}alkyl, heterosyklisk karbonyl, heterosyklisk C_{1-6}alkylkarbonyl, heterosyklisk karbonylC_{1-6}alkyl, heterosyklisk C_{1-6}alkyltio, heterosyklisk C_{1-6}alkylsulfinyl, heterosyklisk C_{1-6}alkylsulfonyl, heterosyklisk aminokarbonyl, heterosyklisk C_{1-6}alkylaminokarbonyl, heterosyklisk aminokarbonylC_{1-6}alkyl, heterosyklisk karboksamido, og heterosyklisk C_{1-6}alkylkarboksamido;

aryl refererer til en C_{6-12}syklisk eller bisyklisk aromatisk ring;

heteroarylene hver uavhengig refererer til en 5- til 12-leddet syklisk eller bisyklisk aromatisk heteroring som har ett eller flere N, O eller S;

heterosyklylene hver uavhengig refererer til en mettet eller delvis umettet 3- til 12-leddet, syklisk eller bisyklisk heteroring med ett eller flere N, O, S, SO eller SO_2, der et karbonatom som danner heterosyklusen eventuelt har en eller flere substituenter valgt fra gruppen som består av C_{1-6}alkyl, hydroksy, hydroksyC_{1-6}alkyl, hydroksykarbonyl, C_{1-6}alkoksy, amino, C_{1-6}alkylamino, di(C_{1-6}alkyl)amino, di(C_{1-6}alkyl)aminoC_{1-6}alkyl, di(C_{1-6}alkyl)aminokarbonyl, heterosyklus, heterosyklisk C_{1-6}alkyl, og heteroaryl, og der, gitt at heterosykluset eventuelt omfatter et nitrogenatom, har nitrogenatomet eventuelt en substituent valgt fra gruppen som består av hydrogenatom, C_{1-6}alkyl, monohalogenoC_{1-6}alkyl, dihalogenoC_{1-6}alkyl, trihalogenoC_{1-6}alkyl, C_{3-6}sykloalkyl, hydroksyC_{2-6}alkyl, C_{1-6}alkoksyC_{2-6}alkyl, C_{1-6}alkylkarbonyl, hydroksyC_{1-6}alkylkarbonyl, C_{1-6}alkoksykarbonyl, karbamoyl, C_{1-6}alkylkarbamoyl, di(C_{1-6}alkyl)karbamoyl, sulfamoyl, C_{1-6}alkylsulfamoyl, di(C_{1-6}alkyl)sulfamoyl, C_{1-6}alkylsulfonyl, aminoC_{2-6}alkyl, C_{1-6}alkylaminoC_{2-6}alkyl, di(C_{1-6}alkyl)aminoC_{2-6}alkyl, di(C_{1-6}alkyl)aminoC_{1-6}alkylkarbonyl, heterosyklus, heterosyklisk oksy, heterosyklisk tio, heterosyklisk sulfinyl, heterosyklisk sulfonyl, heterosyklisk C_{1-6}alkyl, heterosyklisk karbonyl, heterosyklisk C_{1-6}alkylkarbonyl, heterosyklisk C_{1-6}alkylsulfinyl, og heterosyklisk C_{1-6}alkylsulfonyl (hvori, når nitrogenatomet danner tertiært amin, et det eventuelt av en N-oksidform); og eventuelt er C_{1-6}alkylet delvis umettet eller har en C_{3-6}sykloalkylrest, og et karbonatom i heterosyklusen foreligger i en karbonylform.

2. Forbindelsen ifølge krav 1, hvori Z er valgt fra gruppen som består av formlene Z1 til Z203:



Z1 Z2 Z3 Z4 Z5 Z6 Z7 Z8 Z9 Z10



Z11 Z12 Z13 Z14 Z15 Z16 Z17 Z18 Z19 Z20



Z21 Z22 Z23 Z24 Z25 Z26 Z27 Z28 Z29 Z30



Z31 Z32 Z33 Z34 Z35 Z36 Z37 Z38 Z39 Z40



Z41 Z42 Z43 Z44 Z45 Z46 Z47 Z48 Z49 Z50



Z51 Z52 Z53 Z54 Z55 Z56 Z57 Z58 Z59 Z60



Z61 Z62 Z63 Z64 Z65 Z66 Z67 Z68 Z69 Z70



Z71 Z72 Z73 Z74 Z75 Z76 Z77 Z78 Z79 Z80



Z81 Z82 Z83 Z84 Z85 Z86 Z87 Z88 Z89 Z90



Z91 Z92 Z93 Z94 Z95 Z96 Z97 Z98 Z99 Z100



Z101 Z102 Z103 Z104 Z105 Z106 Z107 Z108 Z109 Z110



Z111 Z112 Z113 Z114 Z115 Z116 Z117 Z118 Z119 Z120



Z121 Z122 Z123 Z124 Z125 Z126 Z127 Z128 Z129 Z130



Z131 Z132 Z133 Z134 Z135 Z136 Z137 Z138 Z139 Z140



Z141 Z142 Z143 Z144 Z145 Z146 Z147 Z148 Z149 Z150



Z151 Z152 Z153 Z154 Z155 Z156 Z157 Z158 Z159 Z160



Z161 Z162 Z163 Z164 Z165 Z166 Z167 Z168 Z169 Z170



Z171 Z172 Z173 Z174 Z175 Z176 Z177 Z178 Z179 Z180



Z181 Z182 Z183 Z184 Z185 Z186 Z187 Z188 Z189 Z190



Z191 Z192 Z193 Z194 Z195 Z196 Z197 Z198 Z199 Z200



Z201 Z202 Z203

3. Forbindelsen ifølge krav 1, hvori forbindelsen med formel (I) er valgt fra gruppen som består av:

N-(3-(2-(2-metoksy-4-(4-metylpiperazin-1-yl)fenylamino)tieno[3,2-*d*]pyrimidin-4-yloksy)fenyl)akrylamid;
N-(3-(2-(4-(4-metylpiperazin-1-yl)fenylamino)tieno[3,2-*d*]pyrimidin-4-yloksy)fenyl)akrylamid;
N-(3-(2-(4-(4-*tert*-butyl-piperazin-1-yl)-fenylamino)-tieno[3,2-*d*]pyrimidin-4-yloksy)-fenyl)-akrylamid;
N-(3-(2-(4-(4-(2-fluor-etyl)-piperazin-1-yl)-fenylamino)-tieno[3,2-*d*]pyrimidin-4-yloksy)-fenyl)-akrylamid;
N-(3-(2-(4-(4-(2,2,2-trifluor-etyl)-piperazin-1-yl)-fenylamino)-tieno[3,2-*d*]pyrimidin-4-yloksy)-fenyl)-akrylamid;
N-(3-(2-(4-(4-(2-metoksy-etyl)-piperazin-1-yl)-fenylamino)-tieno[3,2-*d*]pyrimidin-4-yloksy)-fenyl)-akrylamid;
N-(3-(2-(4-(4-(2-hydroksy-etyl)-piperazin-1-yl)-fenylamino)-tieno[3,2-*d*]pyrimidin-4-yloksy)-fenyl)-akrylamid;
N-(3-(2-(4-(4-hydroksy-4-metyl-piperazin-1-yl)-fenylamino)-tieno[3,2-*d*]pyrimidin-4-yloksy)-fenyl)-akrylamid;
N-(3-(2-(4-(3,4,5-trimetyl-piperazin-1-yl)-fenylamino)-tieno[3,2-*d*]pyrimidin-4-yloksy)-fenyl)-akrylamid;
N-(3-(2-(4-(5-metyl-2,5-diaza-bisyklo[2.2.1]hept-2-yl)-fenylamino)-tieno[3,2-*d*]pyrimidin-4-yloksy)-fenyl)-akrylamid;
N-(3-(2-(1-metyl-2-okso-2,3,4,5-tetrahydro-*1H*-benzo[*b*]azepin-7-ylamino)-tieno[3,2-*d*]pyrimidin-4-yloksy)-fenyl)-akrylamid;
N-(3-(2-(2-metoksy-4-(1-metyl-piperidin-4-yl)-fenylamino)-tieno[3,2-*d*]pyrimidin-4-yloksy)-fenyl)-akrylamid;
N-(3-(2-(2-metoksy-4-(1-metyl-piperidin-3-yl)-fenylamino)-tieno[3,2-*d*]pyrimidin-4-yloksy)-fenyl)-akrylamid;
N-(3-(2-(3-fluor-4-(4-metylpiperazin-1-yl)fenylamino)tieno[3,2-*d*]pyrimidin-4-yloksy)fenyl)akrylamid;
Dietyl(4-((4-(3-akrylamidofenoksy)tieno[3,2-*d*]pyrimidin-2-yl)amino)fenyl)fosfonat;
N-(3-(2-(4-[1,4']bipiperidinyl-1'-yl-3-fluor-fenylamino)-tieno[3,2-*d*]pyrimidin-4-yloksy)-fenyl)-akrylamid;
N-(3-((2-((3-klor-4-(4-metylpiperazin-1-yl)fenyl)amino)tieno[3,2-*d*]pyrimidin-4-yl)oksy)fenyl)akrylamid;
N-(3-(2-(4-(1-metylpiperidin-4-ylamino)-3-klorfenylamino)tieno[3,2-*d*]pyrimidin-4-yloksy)fenyl)akrylamid;
N-(3-(2-(2-fluor-4-(4-metylpiperazin-1-yl)fenylamino)tieno[3,2-*d*]pyrimidin-4-yloksy)fenyl)akrylamid;

N-(3-(2-(3-metyl-4-(4-metylpiperazin-1-yl)fenylamino)tieno[3,2-*d*]pyrimidin-4-yloksy)fenyl)akrylamid;
4-((4-(3-akrylamidofenoksy)tieno[3,2-*d*]pyrimidin-2-yl)amino)-2-metyl-*N*(1-metylpiperidin-4-yl)benzamid;
N-(4-metyl-3-(2-(4-(4-metylpiperazin-1-yl)fenylamino)tieno[3,2-*d*]pyrimidin-4-yloksy)fenyl)akrylamid;
N-(4-fluor-3-(2-(4-(4-metyl-piperazin-1-yl)-fenylamino)-tieno[3,2-*d*]pyrimidin-4-yloksy)-fenyl)-akrylamid;
N-(4-metoksy-3-(2-(4-(4-metylpiperazin-1-yl)-fenylamino)tieno[3,2-*d*]pyrimidin-4-yloksy)fenyl)akrylamid;
N-(3-(2-(5-(4-metylpiperazin-1-yl)pyridin-2-ylamino)tieno[3,2-*d*]pyrimidin-4-yloksy)fenyl)akrylamid;
4-metyl-piperazin-1-karboksylsyre (4-(4-(3-akryloylamino-fenoksy)-tieno[3,2-*d*]pyrimidin-2-ylamino)-fenyl)-amid;
N-(4-((4-(3-akrylamidofenoksy)tieno[3,2-*d*]pyrimidin-2-yl)amino)-2-fluorfenyl)-4-metylpiperazin-1-karboksamid;
N-(3-(2-(4-(4-etylpiperazin-1-yl)fenylamino)tieno[3,2-*d*]pyrimidin-4-yloksy)fenyl)akrylamid;
N-(3-(2-(4-(4-isopropyl-piperazin-1-yl)-fenylamino)-tieno[3,2-*d*]pyrimidin-4-yloksy)-fenyl)-akrylamid;
N-(3-(2-(4-(4-(2,2-difluor-etyl)-piperazin-1-yl)-fenylamino)-tieno[3,2-*d*]pyrimidin-4-yloksy)-fenyl)-akrylamid;
N-(3-(2-(4-imidazol-1-yl-fenylamino)-tieno[3,2-d]pyrimidin-4-yloksy)-fenyl)-akrylamid;
N-(3-(2-(4-(piperazin-1-yl)fenylamino)tieno[3,2-*d*]pyrimidin-4-yloksy)fenyl)akrylamid;
N-(3-(2-(4-(4-(2-dimetylamino-acetyl)-piperazin-1-yl)-3-fluor-fenylamino)-tieno[3,2-*d*]pyrimidin-4-yloksy)-fenyl)-akrylamid;
N-(3-(2-(3-klor-4-(piperazin-1-yl)fenylamino)tieno[3,2-d]pyrimidin-4-yloksy)fenyl)akrylamid;
N-(3-(2-(4-(4-(metylsulfonyl)piperazin-1-yl)fenylamino)tieno[3,2-*d*]pyrimidin-4-yloksy)fenyl)akrylamid;
N-(3-(2-(4-(4-acetylpiperazin-1-yl)fenylamino)tieno[3,2-*d*]pyrimidin-4-yloksy)fenyl)akrylamid;
N-(3-(2-(4-(4-(morfolin-4-karbonyl)-piperazin-1-yl)-fenylamino)-tieno[3,2-*d*]pyrimidin-4-yloksy)-fenyl)-akrylamid;
N-(3-(2-(4-(1,4-dimetyl-3-okso-piperazin-2-yl)-fenylamino)-tieno[3,2-*d*]pyrimidin-4-yloksy)-fenyl)-akrylamid;
N-(3-(2-(4-morfolinofenylamino)tieno[3,2-*d*]pyrimidin-4-yloksy)fenyl)akrylamid;

N-(3-((2-((4-((2-(dimetylamino)etyl)amino)fenyl)amino)tieno[3,2-*d*]pyrimidin-4-yl)oksy)fenyl)akrylamid;

N-(3-((2-((4-((2-(4-metylpiperazin-1-yl)etyl)amino)fenyl)amino)tieno[3,2-*d*]pyrimidin-4-yl)oksy)fenyl)akrylamid;

N-(3-(2-(4-tiomorfolinofenylamino)tieno[3,2-*d*]pyrimidin-4-yloksy)fenyl)akrylamid;

N-(3-(2-(4-(1-okso-1λ^4-tiomorfolin-4-yl)-fenylamino)-tieno[3,2-*d*]pyrimidin-4-yloksy)-fenyl)-akrylamid;

(*S*)-*N*-(3-(2-(4-(3-(dimetylamino)pyrrolidin-1-yl)fenylamino)tieno[3,2-*d*]pyrimidin-4-yloksy)fenyl)akrylamid;

N-(3-(2-(4-(4-pyrrolidin-1-yl-piperidin-1-yl)-fenylamino)-tieno[3,2-*d*]pyrimidin-4-yloksy)-fenyl)-akrylamid;

N-(3-(2-(4-[1,4']bipiperidinyl-1'-yl-fenylamino)-tieno[3,2-*d*]pyrimidin-4-yloksy)-fenyl)-akrylamid;

1-(4-(4-(3-akryloylamino-fenoksy)-tieno[3,2-*d*]pyrimidin-2-ylamino)-fenyl)-piperidin-4-karboksylsyredimetylamid;

N-(3-(2-(4-(dimetylamino)fenylamino)tieno[3,2-*d*]pyrimidin-4-yloksy)fenyl)akrylamid;

N-(3-(2-(4-(2-hydroksy-etyl)-fenylamino)-tieno[3,2-*d*]pyrimidin-4-yloksy)-fenyl)-akrylamid;

N-(3-(2-(4-(2-dimetylamino-etyl)-fenylamino)-tieno[3,2-*d*]pyrimidin-4-yloksy)-fenyl)-akrylamid;

N-(3-(2-(3-klor-4-fluorfenylamino)tieno[3,2-*d*]pyrimidin-4-yloksy)fenyl)akrylamid;

N-(3-(2-(4-hydroksyfenylamino)tieno[3,2-*d*]pyrimidin-4-yloksy)fenyl)akrylamid;

N-(3-((2-((4-acetylfenyl)amino)tieno[3,2-*d*]pyrimidin-4-yl)oksy)fenyl)akrylamid;

N-(3-((2-((4-(1,4,5,6-tetrahydropyrimidin-2-yl)fenyl)amino)tieno[3,2-*d*]pyrimidin-4-yl)okso)fenyl)akrylamid;

N-(3-(2-(3-fluor-2-metoksy-4-(4-metyl-piperazin-1-yl)-fenylamino)-tieno[3,2-*d*]pyrimidin-4-yloksy)-fenyl)-akrylamid;

N-(3-(2-(4-(4-(4-etylpiperazin-1-yl)piperidin-1-yl)fenylamino)tieno[3,2-*d*]pyrimidin-4-yloksy)fenyl)akrylamid;

N-(3-(2-(4-(*3R*-imidazol-1-yl-pyrrolidin-1-yl)-fenylamino]-tieno[3,2-*d*]pyrimidin-4-yloksy)-fenyl)-akrylamid;

N-(3-(2-(4-(3-imidazol-1-yl-pyrrolidin-1-yl)-fenylamino)-tieno[3,2-*d*]pyrimidin-4-yloksy)-fenyl)-akrylamid;

N-(3-(2-(4-(4-imidazol-1-yl-piperidin-1-yl)-fenylamino)-tieno[3,2-*d*]pyrimidin-4-yloksy)-fenyl)-akrylamid;

N-(3-(2-(4-(4-dimetylamino-piperidin-1-yl)-fenylamino)-tieno[3,2-*d*]pyrimidin-4-yloksy)-fenyl)-akrylamid;

N-(3-(2-(4-(4-morfolin-4-yl-piperidin-1-yl)-fenylamino)-tieno[3,2-*d*]pyrimidin-4-yloksy)-fenyl)-akrylamid;
N-(3-(2-(3-fluor-4-(4-pyrrolidin-1-yl-piperidin-1-yl)-fenylamino)-tieno[3,2-*d*]pyrimidin-4-yloksy)-fenyl)-akrylamid;
N-(3-(2-(3-fluor-4-(4-morfolin-4-yl-piperidin-1-yl)-fenylamino)-tieno[3,2-*d*]pyrimidin-4-yloksy)-fenyl)-akrylamid;
N-(3-(2-(3-klor-4-1-yl-piperidin-1-yl)-fenylamino)-tieno[3,2-*d*]pyrimidin-4-yloksy)-fenyl)-akrylamid;
N-(3-(2-(3-klor-4-(4-morfolin-4-yl-piperidin-1-yl)-fenylamino)-tieno[3,2-*d*]pyrimidin-4-yloksy)-fenyl)-akrylamid;
N-(3-(2-(4-(4-hydroksypiperidin-1-yl)fenylamino)tieno[3,2-*d*]pyrimidin-4-yloksy)fenyl)akrylamid;
N-(3-((2-((4-(4-(hydroksymetyl)piperidin-1-yl)fenyl)amino)tieno[3,2-*d*]pyrimidin-4-yl)oksy)fenyl)akrylamid;
N-(3-((2-((4-(4-(2-hydroksyetyl)piperidin-1-yl)fenyl)amino)tieno[3,2-*d*]pyrimidin-4-yl)oksy)fenyl)akrylamid;
N-(3-(2-(4-(4-(etylsulfonyl)piperazin-1-yl)fenylamino)tieno[3,2-*d*]pyrimidin-4-yloksy)fenyl)akrylamid;
N-(3-(2-(4-((4-etylpiperazin-1-yl)metyl)fenylamino)tieno[3,2-*d*]pyrimidin-4-yloksy)fenyl)akrylamid;
N-(3-(2-(4-dietylaminometyl-fenylamino)-tieno[3,2-*d*]pyrimidin-4-yloksy)-fenyl)-akrylamid;
N-(3-(2-(4-(4-morfolin-4-yl-piperidin-1-ylmetyl)-fenylamino)-tieno[3,2-*d*]pyrimidin-4-yloksy)-fenyl)-akrylamid;
(*E*)-*N*-(3-((2-((4-(3-(dimetylamino)prop-1-en-1-yl)fenyl)amino)tieno[3,2-*d*]pyrimidin-4-yl)oksy)fenyl)akrylamid;
N-(3-((2-((4-((1-metylpiperidin-4-yl)amino)fenyl)amino)tieno[3,2-*d*]pyrimidin-4-yl)oksy)fenyl)akrylamid;
N-(3-(2-(4-dietylaminometyl-2-metoksy-fenylamino)-tieno[3,2-*d*]pyrimidin-4-yloksy)-fenyl)-akrylamid;
N-(3-(2-(4-((4-metylpiperazin-1-yl)metyl)fenylamino)tieno[3,2-*d*]pyrimidin-4-yloksy)fenyl)akrylamid;
N-(3-(2-(3-fluor-4-(4-metyl-piperazin-1-ylmetyl)-fenylamino)-tieno[3,2-*d*]pyrimidin-4-yloksy)-fenyl)-akrylamid;
N-(3-(2-(4-(piperidin-1-ylmetyl)fenylamino)tieno[3,2-*d*]pyrimidin-4-yloksy)fenyl)akrylamid;
N-(3-(2-(4-azetidin-1-ylmetyl-fenylamino)-tieno[3,2-*d*]pyrimidin-4-yloksy)-fenyl)-akrylamid;

N-(3-(2-(4-pyrrolidin-1-ylmetyl-fenylamino)-tieno[3,2-*d*]pyrimidin-4-yloksy)-fenyl)-akrylamid;
N-(3-(2-(4-(morfolinometyl)fenylamino)tieno[3,2-*d*]pyrimidin-4-yloksy)fenyl)akrylamid;
N-(3-((2-((4-((3-(dimetylamino)pyrrolidin-1-yl)metyl)fenyl)amino)tieno[3,2-*d*]pyrimidin-4-yl)oksy)fenyl)akrylamid;
N-(3-((2-((4-((4-hydroksypiperidin-1-yl)metyl)fenyl)amino)tieno[3,2-*d*]pyrimidin-4-yl)oksy)fenyl)akrylamid;
N-(3-((2-((4-((4-(dimetylamino)piperidin-1-yl)metyl)fenyl)amino)tieno[3,2-*d*]pyrimidin-4-yl)oksy)fenyl)akrylamid;
Dimetyl(4-((4-(3-akrylamidofenoksy)tieno[3,2-*d*]pyrimidin-2-yl)amino)benzylfosfonat;
N-(3-(2-(4-((dimetylamino)metyl)-3-fluorfenylamino)tieno[3,2-*d*]pyrimidin-4-yloksy)fenyl)akrylamid;
N-(3-(2-(4-((3-(dimetylamino)pyrrolidin-1-yl)metyl)3-fluorfenylamino)tieno[3,2-*d*]pyrimidin-4-yloksy)fenyl)akrylamid;
N-(3-(2-(4-((4-(dimetylamino)piperidin-1-yl)metyl)3-fluorfenylamino)tieno[3,2-*d*]pyrimidin-4-yloksy)fenyl)akrylamid;
N-(3-(2-(4-((1-metylpiperidin-4-ylamino)metyl)-3-fluorfenylamino)-tieno[3,2-*d*]pyrimidin-4-yloksy)-fenyl)-akrylamid;
N-(3-(2-(4-dimetylaminometyl-2-metyl-fenylamino)-tieno[3,2-*d*]pyrimidin-4-yloksy)-fenyl)-akrylamid;
N-(3-(2-(4-((4-(syklopropylmetyl)piperazin-1-yl)metyl)fenylamino)tieno[3,2-*d*]pyrimidin-4-yloksy)fenyl)akrylamid;
N-(3-(2-(4-((4-(1-metylpiperidin-4-yl)piperazin-1-yl)metyl)fenylamino)tieno[3,2-*d*]pyrimidin-4-yloksy)fenyl)akrylamid;
N-(3-(2-(4-metansulfonylmetyl-fenylamino)-tieno[3,2-*d*]pyrimidin-4-yloksy)-fenyl)-akrylamid;
N-(3-(2-(4-(2-metansulfonyl-etyl)-fenylamino)-tieno[3,2-*d*]pyrimidin-4-yloksy)-fenyl)-akrylamid;
N-(3-(2-(3-klor-4-(4-(1-metyl-piperidin-4-yl)piperazin-1-ylmetyl)fenylamino)-tieno[3,2-*d*]pyrimidin-4-yloksy)-fenyl)-akrylamid;
N-(3-(2-(4-(4-(1-metylpiperidin-4-yl)piperazin-1-yl)fenylamino)tieno[3,2-*d*]pyrimidin-4-yloksy)fenyl)akrylamid;
N-(3-(2-(4-(4-sykloheksyl-piperazin-1-yl)-fenylamino)-tieno[3,2-*d*]pyrimidin-4-yloksy)-fenyl)-akrylamid;
N-(3-(2-(5-(4-etylpiperazin-1-yl)pyridin-2-ylamino)tieno[3,2-*d*]pyrimidin-4-yloksy)fenyl)akrylamid;
N-(3-(2-(5-(4-(2-hydroksy-etyl)-piperazin-1-yl)-piridin-2-ylamino)-tieno[3,2-*d*]pyrimidin-4-yloksy)-fenyl)-akrylamid;

N-(3-(2-(4-(1-(4-etylpiperazin-1-yl)etyl)fenylamino)tieno[3,2-*d*]pyrimidin-4-yloksy)fenyl)akrylamid;
N-(3-(2-(4-(4-etylpiperazin-1-karbonyl)fenylamino)tieno[3,2-*d*]pyrimidin-4-yloksy)fenyl)akrylamid;
N-(3-(2-(4-(4-(2-hydroksy-acetyl)-piperazin-1-yl)-fenylamino)-tieno[3,2-*d*]pyrimidin-4-yloksy)-fenyl)-akrylamid;
N-(3-(2-(4-(4-(2-dimetylamino-acetyl)-piperazin-1-yl)-fenylamino)-tieno[3,2-*d*]pyrimidin-4-yloksy)-fenyl)-akrylamid;
2-(4-((4-(3-akrylamidofenoksy)tieno[3,2-*d*]pyrimidin-2-yl)amino)fenyl)eddiksyre;
N-(3-((2-((4-(metylsulfinyl)fenyl)amino)tieno[3,2-*d*]pyrimidin-4-yl)oksy)fenyl)akrylamid;
N-(3-((2-((4-(metylsulfonyl)fenyl)amino)tieno[3,2-*d*]pyrimidin-4-yl)oksy)fenyl)akrylamid;
4-((4-(3-akrylamidofenoksy)tieno[3,2-*d*]pyrimidin-2-yl)amino)-*N*-metylbenzamid;
4-((4-(3-akrylamidofenoksy)tieno[3,2-*d*]pyrimidin-2-yl)amino)-*N*,*N*-dimetylbenzamid;
N-(3-((2-((4-(morfolin-4-karbonyl)fenyl)amino)tieno[3,2-*d*]pyrimidin-4-yl)oksy)fenyl)akrylamid;
N-(3-((2-((4-(4-metylpiperazin-1-karbonyl)fenyl)amino)tieno[3,2-*d*]pyrimidin-4-yl)oksy)fenyl)akrylamid;
N-(3-(2-(4-(4-(1-metyl-piperidin-4-yl)-piperazin-1-karbonyl)-fenylamino)-tieno[3,2-*d*]pyrimidin-4-yloksy)-fenyl)-akrylamid;
N-(3-(2-(4-(4-hydroksy-piperidin-1-karbonyl)-fenylamino)-tieno[3,2-*d*]pyrimidin-4-yloksy)-fenyl)-akrylamid;
N-(3-(2-(4-(3-metylamino-pyrrolidin-1-karbonyl)-fenylamino)-tieno[3,2-*d*]pyrimidin-4-yloksy)-fenyl)-akrylamid;
N-(3-(2-(4-(3-dimetylamino-pyrrolidin-1-karbonyl)-fenylamino)-tieno[3,2-*d*]pyrimidin-4-yloksy)-fenyl)-akrylamid;
4-(4-(3-akryloylamino-fenoksy)-tieno[3,2-*d*]pyrimidin-2-ylamino)-*N*-(2-dimetylamino-etyl)-benzamid;
N-(3-(2-(3-klor-4-(4-etylpiperazin-1-karbonyl)fenylamino)tieno[3,2-*d*]pyrimidin-4-yloksy)fenyl)akrylamid;
N-(3-((2-((3-klor-4-((2-(dimetylamino)etyl)amino)fenyl)amino)tieno[3,2-*d*]pyrimidin-4-yl)oksy)fenyl)akrylamid;
4-(4-(3-akryloylamino-fenoksy)-tieno[3,2-*d*]pyrimidin-2-ylamino)-2-klor-*N*,*N*-dimetyl-benzamid;
N-(3-(2-(3-klor-4-(4-etansulfonyl-piperazin-1-karbonyl)-fenylamino)-tieno[3,2-*d*]pyrimidin-4-yloksy)-fenyl)-akrylamid;
4-((4-(3-akrylamidofenoksy)tieno[3,2-*d*]pyrimidin-2-yl)amino-2-klor-*N*-(1-metylpiperidin-4-yl)benzamid;

N-(3-(2-(4-(4-etylpiperazin-1-ylsulfonyl)fenylamino)tieno[3,2-*d*]pyrimidin-4-yloksy)fenyl)akrylamid;
N-(3-((2-((4-((metylsulfinyl)metyl)fenyl)amino)tieno[3,2-*d*]pyrimidin-4-yl)oksy)fenyl)akrylamid;
N-(3-((2-((4-(2-(metylsulfinyl)etyl)fenyl)amino)tieno[3,2-*d*]pyrimidin-4-yl)oksy)fenyl)akrylamid;
N-(3-((2-((4-sulfamoylfenyl)amino)tieno[3,2-*d*]pyrimidin-4-yl)oksy)fenyl)akrylamid;
N-(3-((2-((4-(morfolinosulfonyl)fenyl)amino)tieno[3,2-*d*]pyrimidin-4-yl)oksy)fenyl)akrylamid;
N-(3-((2-((4-(*N*-syklopropylsulfamoyl)fenyl)amino)tieno[3,2-*d*]pyrimidin-4-yl)oksy)fenyl)akrylamid;
N-(3-((2-((4-(*N*-(2-(dimetylamino)etyl)sulfamoyl)fenyl)amino)tieno[3,2-*d*]pyrimidin-4-yl)oksy)fenyl)akrylamid;
N-(3-((2-((4-(*N*-(1-metylpiperidin-4-yl)sulfamoyl)fenyl)amino)tieno[3,2-*d*]pyrimidin-4-yl)oksy)fenyl)akrylamid;
N-(3-((2-((4-(*N*-(1-isopropylpiperidin-4-yl)sulfamoyl)fenyl)amino)tieno[3,2-*d*]pyrimidin-4-yl)oksy)fenyl)akrylamid;
3-(dimetylamino)propyl-4-((4-(3-akrylamidofenoksy)tieno[3,2-*d*]pyrimidin-2-yl)amino)benzoat;
N-(3-(2-(4-(2-(4-etylpiperazin-1-yl)etyl)fenylamino)tieno[3,2-*d*]pyrimidin-4-yloksy)fenyl)akrylamid;
N-(3-(2-(4-(2-piperidin-1-yl-etyl)-fenylamino)-tieno[3,2-*d*]pyrimidin-4-yloksy)-fenyl)-akrylamid;
N-(3-(2-(4-(1,1-diokso-1λ^6-tiomorfolin-4-yl)-fenylamino)-tieno[3,2-*d*]pyrimidin-4-yloksy)-fenyl)-akrylamid;
N-(3-(2-(4-(2-(4-etylpiperazin-1-yl)acetyl)fenylamino)tieno[3,2-*d*]pyrimidin-4-yloksy)fenyl)akrylamid;
N-(3-(2-(4-(1-etylpiperidin-4-yloksy)fenylamino)tieno[3,2-*d*]pyrimidin-4-yloksy)fenyl)akrylamid;
N-(3-(2-(3-fluor-4-(1-metyl-piperidin-4-yloksy)-fenylamino)-tieno[3,2-*d*]pyrimidin-4-yloksy)-fenyl)-akrylamid;
N-(3-(2-(4-(2-morfolinoetoksy)fenylamino)tieno[3,2-*d*]pyrimidin-4-yloksy)fenyl)akrylamid;
N-(3-(2-(4-(2-metoksy-etoksy)-fenylamino)-tieno[3,2-*d*]pyrimidin-4-yloksy)-fenyl)-akrylamid;
N-(3-((2-((4-(2-(dimetylamino)etoksy)fenyl)amino)tieno[3,2-*d*]pyrimidin-4-yl)oksy)fenyl)akrylamid;

N-(3-((2-((4-(2-(dietylamino)etoksy)fenyl)amino)tieno[3,2-*d*]pyrimidin-4-yl)oksy)fenyl)akrylamid;
N-(3-((2-((4-(2-(pyrrolidin-1-yl)etoksy)fenyl)amino)tieno[3,2-*d*]pyrimidin-4-yl)oksy)fenyl)akrylamid;
N-(3-((2-((2,3,4,5-tetrahydrobenzo[*b*][1,4]oksazepin-7-yl)amino)tieno[3,2-*d*]pyrimidin-4-yl)oksy)fenyl)akrylamid;
N-(3-(2-(2,3-dihydro-benzo[1,4]dioksin-6-ylamino)-tieno[3,2-*d*]pyrimidin-4-yloksy)-fenyl)-akrylamid;
N-(3-(2-(3-fluor-4-(2-metoksy-etoksy)-fenylamino)-tieno[3,2-*d*]pyrimidin-4-yloksy)-fenyl)-akrylamid;
N-(3-(2-(4-(2-dimetylamino-etoksy)-3-fluor-fenylamino)-tieno[3,2-*d*]pyrimidin-4-yloksy)-fenyl)-akrylamid;
N-(3-(2-(4-(2-dietylamino-etoksy)-3-fluor-fenylamino)-tieno[3,2-*d*]pyrimidin-4-yloksy)-fenyl)-akrylamid;
N-(3-(2-(3-fluor-4-(2-(4-metyl-piperazin-1-yl)-etoksy)-fenylamino)-tieno[3,2-*d*]pyrimidin-4-yloksy)-fenyl)-akrylamid;
N-(3-(2-(3-metoksy-4-(2-morfolin-4-yl-etoksy)-fenylamino)-tieno[3,2-*d*]pyrimidin-4-yloksy)-fenyl)-akrylamid;
(*E*)-4-(dimetylamino)-*N*-(3-(2-(4-(4-metylpiperazin-1-yl)fenylamino)tieno[3,2-*d*]pyrimidin-4-yloksy)fenyl)but-2-enamid;
N-(3-(2-(4-(4-metylpiperazin-1-yl)fenylamino)tieno[3,2-*d*]pyrimidin-4-ylamino)fenyl)akrylamid;
N-(3-(2-(4-(4-etyl-piperazin-1-yl)-fenylamino)-tieno[3,2-*d*]pyrimidin-4-ylamino)-fenyl)-akrylamid;
N-(3-(2-(4-(4-isopropyl-piperazin-1-yl)-fenylamino)-tieno[3,2-*d*]pyrimidin-4-ylamino)-fenyl)-akrylamid;
N-(3-(2-(4-(1-metyl-piperidin-4-yl)-fenylamino)-tieno[3,2-*d*]pyrimidin-4-ylamino)-fenyl)-akrylamid;
N-(3-(2-(4-(1-metyl-piperidin-3-yl)-fenylamino)-tieno[3,2-*d*]pyrimidin-4-ylamino)-fenyl)-akrylamid;
N-(3-(2-(4-dimetylaminometyl-fenylamino)-tieno[3,2-*d*]pyrimidin-4-ylamino)-fenyl)-akrylamid;
N-(3-(2-(4-piperidin-1-ylmetyl-fenylamino)-tieno[3,2-*d*]pyrimidin-4-ylamino)-fenyl)-akrylamid;
N-(3-(2-(4-(2-dimetylamino-etyl)-fenylamino)-tieno[3,2-*d*]pyrimidin-4-ylamino)-fenyl)-akrylamid;
N-(3-((2-((4-(2-(4-metylpiperazin-1-yl)etyl)fenyl)amino)tieno[3,2-*d*]pyrimidin-4-yl)amino)fenyl)akrylamid;

N-(3-(2-(4-(2-dimetylamino-etoksy)-fenylamino)-tieno[3,2-*d*]pyrimidin-4-ylamino)-fenyl)-akrylamid;
N-(3-(2-(4-(3-dimetylamino-propoksy)-fenylamino)-tieno[3,2-*d*]pyrimidin-4-ylamino)-fenyl)-akrylamid;
N-(3-(2-(3-fluor-4-(4-metyl-piperazin-1-yl)-fenylamino)-tieno[3,2-*d*]pyrimidin-4-ylamino)-fenyl)-akrylamid;
N-(3-(2-(3-fluor-4-(1-metyl-piperidin-4-yl)-fenylamino)-tieno[3,2-*d*]pyrimidin-4-ylamino)-fenyl)-akrylamid;
N-(3-(2-(3-fluor-4-(1-metyl-piperidin-4-ylamino)-fenylamino)-tieno[3,2-*d*]pyrimidin-4-ylamino)-fenyl)-akrylamid;
N-(3-(2-(2-metoksy-4-piperidin-1-ylmetyl-fenylamino)-tieno[3,2-*d*]pyrimidin-4-ylamino)-fenyl)-akrylamid;
N-(4-fluor-3-(2-(4-(4-metyl-piperazin-1-yl)-fenylamino)-tieno[3,2-*d*]pyrimidin-4-ylamino)-fenyl)-akrylamid;
N-(4-fluor-3-(2-(3-fluor-4-(4-metyl-piperazin-1-yl)-fenylamino)-tieno[3,2-*d*]pyrimidin-4-ylamino)-fenyl)-akrylamid;
N-(3-(2-(4-(4-metylpiperazin-1-yl)fenylamino)tieno[3,2-*d*]pyrimidin-4-yltio)fenyl)akrylamid;
N-(3-(2-(3-fluor-4-(1-metyl-piperidin-4-yl)-fenylamino)-tieno[3,2-*d*]pyrimidin-4-ylsulfanyl)-fenyl)-akrylamid;
N-(3-(2-(3-fluor-4-morfolin-4-yl-fenylamino)-tieno[3,2-*d*]pyrimidin-4-ylsulfanyl)-fenyl)-akrylamid;
(*E*)-4-(dimetylamino)-*N*-(3-(2-(4-(4-metylpiperazin-1-yl)fenylamino)tieno[3,2-*d*]pyrimidin-4-yltio)fenyl)but-2-enamid;
N-(3-(2-(4-(4-metylpiperazin-1-yl)fenylamino)tieno[3,2-*d*]pyrimidin-4-ylsulfinyl)fenyl)akrylamid;
(*Z*)-3-klor-*N*-(3-(2-(4-(4-metylpiperazin-1-yl)fenylamino)tieno[3,2-*d*]pyrimidin-4-yloksy)fenyl)akrylamid;
(*E*)-3-klor-*N*-(3-(2-(4-(4-metylpiperazin-1-yl)fenylamino)tieno[3,2-*d*]pyrimidin-4-yloksy)fenyl)akrylamid;
N-(3-(2-(4-(4-etylpiperazin-1-yl)-2-metoksyfenylamino)tieno[3,2-*d*]pyrimidin-4-yloksy)fenyl)akrylamid;
N-(3-(2-(2-metoksy-4-morfolinofenylamino)tieno[3,2-*d*]pyrimidin-4-yloksy)fenyl)akrylamid;
4-((4-(3-akrylamidofenoksy)tieno[3,2-*d*]pyrimidin-2-yl)amino)-2-metoksy-*N*-(1-metylpiperidin-4-yl)benzamid;
N-(3-(2-(4-(piperidin-1-yl)fenylamino)tieno[3,2-*d*]pyrimidin-4-yloksy)fenyl)akrylamid;
N-(3-(2-(4-(pyrrolidin-1-yl)fenylamino)tieno[3,2-*d*]pyrimidin-4-yloksy)fenyl)akrylamid;

1-(4-((4-(3-akrylamidofenoksy)tieno[3,2-*d*]pyrimidin-2-yl)amino)fenyl)piperidin-4-karboksylsyre;

N-(3-(2-(4-(4-dimetylaminometyl-piperidin-1-yl)-fenylamino)-tieno[3,2-*d*]pyrimidin-4-yloksy)-fenyl)-akrylamid;

N-(3-(2-(4-1-ylmetyl-piperidin-1-yl)-fenylamino)-tieno[3,2-*d*]pyrimidin-4-yloksy)-fenyl)-akrylamid;

N-(3-(2-(4-(1-metyl-1,2,3,6-tetrahydro-piridin-4-yl)-fenylamino)-tieno[3,2-*d*]pyrimidin-4-yloksy)-fenyl)-akrylamid;

N-(3-(2-(4-(1-metyl-piperidin-4-yl)-fenylamino)-tieno[3,2-*d*]pyrimidin-4-yloksy)-fenyl)-akrylamid;

N-(3-(2-(4-(1-etyl-piperidin-4-yl)-fenylamino)-tieno[3,2-*d*]pyrimidin-4-yloksy)-fenyl)-akrylamid;

N-(3-(2-(4-(1-isopropyl-piperidin-4-yl)-fenylamino)-tieno[3,2-*d*]pyrimidin-4-yloksy)-fenyl)-akrylamid;

N-(3-(2-(4-(1-metyl-piperidin-3-yl)-fenylamino)-tieno[3,2-*d*]pyrimidin-4-yloksy)-fenyl)-akrylamid;

N-(3-(2-(4-dimetylaminometyl-fenylamino)-tieno[3,2-*d*]pyrimidin-4-yloksy)-fenyl)-akrylamid;

N-(3-(2-(3-klor-4-(1-metyl-piperidin-4-yl)-fenylamino)-tieno[3,2-*d*]pyrimidin-4-yloksy)-fenyl)-akrylamid;

4-(4-(3-akrylamidofenoksy)tieno[3,2-*d*]pyrimidin-2-ylamino)-*N*(2-(pyrrolidin-1 -yl)etyl)benzamid;

N-(3-((2-((4-(2-((1-metylpiperidin-4-yl)amino)-2-oksoetyl)fenyl)amino)tieno[3,2-*d*]pyrimidin-4-yl)oksy)fenyl)akrylamid;

N-(3-(2-(4-(3-piperidin-1-yl-propenyl)-fenylamino)-tieno[3,2-*d*]pyrimidin-4-yloksy)-fenyl)-akrylamid;

N-(3-(2-(4-(3-pyrrolidin-1-yl-propionylamino)-fenylamino)-tieno[3,2-*d*]pyrimidin-4-yloksy)-fenyl)-akrylamid;

4-((4-(3-akrylamidofenoksy)tieno[3,2-*d*]pyrimidin-2-yl)amino-*N*-(tetrahydro-*2H*-pyran-4-yl)benzamid;

4-((4-(3-akrylamidofenoksy)tieno[3,2-*d*]pyrimidin-2-yl)amino-*N*-(1-metylpiperidin-4-yl)benzamid;

4-((4-(3-akrylamidofenoksy)tieno[3,2-*d*]pyrimidin-2-yl)amino)-N-(1-isopropylpiperidin-4-yl)benzamid;

4-(4-(3-akryloylamino-fenoksy)-tieno[3,2-*d*]pyrimidin-2-ylamino)-3-metoksy-*N*-(2-pyrrolidin-1-yl-etyl)-benzamid;

N-(3-(2-(4-(4-(*N*,*N*-dimetylsulfamoyl)piperazin-1-yl)fenylamino)tieno[3,2-*d*]pyrimidin-4-yloksy)fenyl)akrylamid;

N-(3-(2-(4-(2-(4-(etylsulfonyl)piperazin-1-yl)etyl)fenylamino)tieno[3,2-*d*]pyrimidin-4-yloksy)fenyl)akrylamid;
N-(3-(2-(6-(4-metylpiperazin-1-yl)pyridin-3-ylamino)tieno[3,2-*d*]pyrimidin-4-yloksy)fenyl)akrylamid;
N-(3-((2-(piridin-3-ylamino)tieno[3,2-*d*]pyrimidin-4-yl)oksy)fenyl)akrylamid;
N-(3-((2-((6-morfolinopiridin-3-yl)amino)tieno[3,2-*d*]pyrimidin-4-yl)oksy)fenyl)akrylamid;
N-(3-((2-((6-(4-isopropylpiperazin-1-yl)pyridin-3-yl)amino)tieno[3,2-*d*]pyrimidin-4-yl)oksy)fenyl)akrylamid;
N-(3-((2-((6-(4-(1-metylpiperidin-4-yl)piperazin-1-yl)pyridin-3-yl)amino)tieno[3,2-*d*]pyrimidin-4-yl)oksy)fenyl)akrylamid;
N-(3-((2-((6-(4-(2-(dimetylamino)etyl)piperazin-1-yl)pyridin-3-yl)amino)tieno[3,2-*d*]pyrimidin-4-yl)oksy)fenyl)akrylamid;
N-(3-((2-((6-(4-(dimetylamino)piperidin-1-yl)pyridin-3-yl)amino)tieno[3,2-*d*]pyrimidin-4-yl)oksy)fenyl)akrylamid;
N-(3-((2-((6-(4-(pyrrolidin-1-yl)piperidin-1-yl)pyridin-3-yl)amino)tieno[3,2-*d*]pyrimidin-4-yl)oksy)fenyl)akrylamid;
N-(3-((2-((6-([1,4'-bipiperidin]-1'-yl)pyridin-3-yl)amino)tieno[3,2-*d*]pyrimidin-4-yl)oksy)fenyl)akrylamid;
N-(3-((2-((6-((4-metylpiperazin-1-yl)metyl)pyridin-3-yl)amino)tieno[3,2-*d*]pyrimidin-4-yl)oksy)fenyl)akrylamid;
N-(3-((2-((6-((2-(piperidin-1-yl)etyl)amino)pyridin-3-yl)amino)tieno[3,2-*d*]pyrimidin-4-yl)oksy)fenyl)akrylamid;
N-(3-((2-((6-((1-isopropylpiperidin-4-yl)amino)pyridin-3-yl)amino)tieno[3,2-*d*]pyrimidin-4-yl)oksy)fenyl)akrylamid;
N-(3-((2-((6-(metylsulfinyl)pyridin-3-yl)amino)tieno[3,2-*d*]pyrimidin-4-yl)oksy)fenyl)akrylamid;
N-(3-(2-(3-fluor-4-morfolinofenylamino)tieno[3,2-*d*]pyrimidin-4-yloksy)fenyl)akrylamid;
N-(3-((2-((3-fluor-4-((1-metylpiperidin-4-yl)amino)fenyl)amino)tieno[3,2-*d*]pyrimidin-4-yl)oksy)fenyl)akrylamid;
N-(3-((3-fluor-4-((1-isopropylpiperidin-4-yl)amino)fenyl)amino)tieno[3,2-*d*]pyrimidin-4-yl)oksy)fenyl)akrylamid;
N-(3-(2-(3-fluor-4-(4-(metylsulfonyl)piperazin-1-yl)fenylamino)tieno[3,2-*d*]pyrimidin-4-yloksy)fenyl)akrylamid;
N-(3-(2-(4-(4-(etansulfonylpiperazin-1-yl)-3-fluor-fenylamino)tieno[3,2-*d*]pyrimidin-4-yloksy)-fenyl)akrylamid;
N-(3-(2-(4-(2,6-*cis*-dimetylmorfolino)-3-fluorfenylamino)tieno[3,2-*d*]pyrimidin-4-yloksy)fenyl)akrylamid;

N-(3-(2-(3-fluor-4-(1-metyl-piperidin-4-yl)-fenylamino)-tieno[3,2-*d*]pyrimidin-4-yloksy)-fenyl)-akrylamid;
N-(3-(2-(3-fluor-4-(1-metyl-piperidin-3-yl)-fenylamino)-tieno[3,2-*d*]pyrimidin-4-yloksy)-fenyl)-akrylamid;
N-(3-(2-(3-fluor-4-(2-morfolin-4-yl-etoksy)fenylamino)-tieno[3,2-*d*]pyrimidin-4-yloksy)-fenyl)-akrylamid;
N-(3-((2-((4-((2-(dimetylamino)etyl)amino)-3-fluorfenyl)amino)tieno[3,2-*d*]pyrimidin-4-yl)oksy)fenyl)akrylamid;
N-(3-((2-((3,5-difluor-4-(4-metylpiperazin-1-yl)fenyl)amino)tieno[3,2-*d*]pyrimidin-4-yl)oksy)fenyl)akrylamid;
N-(3-((2-((4-((2-(dimetylamino)etyl)amino)-3,5-difluorfenyl)amino)tieno[3,2-*d*]pyrimidin-4-yl)oksy)fenyl)akrylamid;
N-(3-((2-((3,5-difluor-4-((1-metylpiperidin-4-yl)amino)fenyl)tieno[3,2-*d*]pyrimidin-4-yl)oksy)fenyl)akrylamid;
N-(3-(2-(4-(1-amino-syklopropyl)-fenylamino)-tieno[3,2-*d*]pyrimidin-4-yloksy)-fenyl)-akrylamid;
N-(3-(2-[1-(2-dimetylamino-acetyl)-2,3-dihydro-1*H*-indol-5-ylamino]-tieno[3,2-d]pyrimidin-4-yloksy)-fenyl)-akrylamid; og
N-(3-(2-(1-metyl-*1H*-indol-5-ylamino)-tieno[3,2-*d*]pyrimidin-4-yloksy)-fenyl)-akrylamid.

4. Anvendelse av forbindelsen ifølge krav 1 for fremstilling av et medikament for å forhindre eller behandle kreftformer, svulster, inflammatoriske sykdommer, autoimmune sykdommer eller immunologisk medierte sykdommer.

5. Anvendelsen ifølge krav 4, hvori kreftene eller svulstene induseres av en epidermal vekstfaktorreseptor (EGFR) tyrosinkinase eller en mutant derav.

6. Anvendelsen ifølge krav 4, hvori kreftene, svulstene, de inflammatoriske sykdommene, de autoimmune sykdommene eller immunologisk medierte sykdommene medieres av minst en kinase valgt fra gruppen som består av Brutons tyrosinkinase (BTK), janus kinase 3 (JAK3) , interleukin-2-induserende T-cellekinase (ITK), hvilende lymfocyttkinase (RLK) og benmargtyrosinkinase (BMX).

7. Anvendelsen ifølge krav 4, hvori kreftene, svulstene, de inflammatoriske sykdommene, de autoimmune sykdommene eller immunologisk medierte sykdommene medieres av abnomalt aktiverte B-lymfocytter, T-lymfocytter eller begge deler.

8. Anvendelsen ifølge krav 4, hvori de inflammatoriske sykdommene, de autoimmune sykdommene eller de immunologisk medierte sykdommene er leddgikt, revmatoid artritt, spondyloartropati, giktartritt, slitasjegikt, juvenil artritt, annen artrittisk tilstand, lupus, systemisk lupus erytematose (SLE), hudrelatert sykdom, psoriasis, eksem, dermatitt, atopisk dermatitt, smerte, pulmonær lidelse, lungebetennelse, voksen respiratorisk distress-syndrom (ARDS), pulmonal sarkoidose, kronisk pulmonar inflammasjonssykdom, kronisk obstruktiv lungesykdom (KOLS), kardiovaskulær sykdom, arteriosklerose, hjerteinfarkt, kongestiv hjertesvikt, hjertereperfusjonsskade, inflammatorisk tarmsykdom, Crohns sykdom, ulcerøs kolitt, irritabelt tarmsyndrom, astma, Sjøgrens syndrom, autoimmunitetstyroidsykdom, urticaria (cnidosie), multippel sklerose, skleroderma, organtransplantasjonsavstøtning, heteroplastisk transplantat, idiopatisk trombocytopenisk purpura (ITP), Parkinsons sykdom, Alzheimers sykdom, diabetesforbundet sykdom, betennelse, bekkenbetennelsessykdom, allergisk rhinitt, allergisk bronkitt, allergisk bihulebetennelse, leukemi, lymfom, B-cellelymfom, T-cellelymfom, myelom, akutt lymfoid leukemi (ALL), kronisk lymfoid leukemi (CLL), akutt myeloid leukemi (AML), kronisk myeloid leukemi (CML), hårcelleleukemi, Hodgkins sykdom, ikke-Hodgkins lymfom, multippel myelom, myelodysplastisk syndrom (MDS), myeloproliferative neoplasmer (MPN), diffus stor-B-cellelymfom eller follikulært lymfom.

9. Anvendelsen ifølge krav 4, som administreres i kombinasjon med et anti-kreftmiddel valgt fra gruppen som består av: cellesignaltransduksjonsinhibitorer, mitoseinhibitorer, alkyleringsmidler, anti-metabolitter, interkalerende anti-kreftmidler, topoisomeraseinhibitorer, immunoterapiske midler, antihormonale midler og en blanding derav.

10. Anvendelsen ifølge krav 4, som administreres i kombinasjon med et terapeutisk middel valgt fra gruppen som består av: steroidlegemidler, metotreksater, leflunomider, anti-TNFα-midler, kalsinurininhibitorer, antihistaminlegemidler, og en blanding derav.

11. Farmasøytisk sammensetning for anvendelse i en fremgangsmåte for forebygging eller behandling av kreft, svulster, inflammatoriske sykdommer, autoimmune sykdommer eller immunologisk medierte sykdommer som omfatter forbindelsen med formel (I) eller dets farmasøytisk akseptable salt ifølge krav 1 som en aktiv bestanddel.

12. Forbindelse ifølge et hvilket som helst av kravene 1 til 3 for anvendelse ved behandling.

13. Forbindelse ifølge et hvilket som helst av kravene 1 til 3 for anvendelse i en fremgangsmåte for forebygging eller behandling av kreftformer, svulster, inflammatoriske sykdommer, autoimmune sykdommer eller immunologisk medierte sykdommer.

14. Forbindelsen for anvendelse ifølge krav 13, hvori sykdommen er som definert i et hvilket som helst av kravene 5 til 8.

15. Forbindelsen ifølge krav 1, hvori forbindelsen er



eller et farmasøytisk akseptabelt salt derav.